PMC:7228307 / 50828-50984 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1007","span":{"begin":60,"end":66},"obj":"Gene"},{"id":"1014","span":{"begin":36,"end":48},"obj":"Chemical"}],"attributes":[{"id":"A1007","pred":"tao:has_database_id","subj":"1007","obj":"Gene:1493"},{"id":"A1014","pred":"tao:has_database_id","subj":"1014","obj":"MESH:C520704"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T400","span":{"begin":67,"end":75},"obj":"Body_part"},{"id":"T401","span":{"begin":97,"end":105},"obj":"Body_part"},{"id":"T402","span":{"begin":148,"end":153},"obj":"Body_part"}],"attributes":[{"id":"A400","pred":"fma_id","subj":"T400","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A401","pred":"fma_id","subj":"T401","obj":"http://purl.org/sig/ont/fma/fma13478"},{"id":"A402","pred":"fma_id","subj":"T402","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":125,"end":129},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0008734"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T862","span":{"begin":60,"end":66},"obj":"http://purl.obolibrary.org/obo/PR_000001852"},{"id":"T863","span":{"begin":148,"end":153},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T92845","span":{"begin":26,"end":35},"obj":"Chemical"}],"attributes":[{"id":"A62143","pred":"chebi_id","subj":"T92845","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T226","span":{"begin":148,"end":153},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1007","span":{"begin":60,"end":66},"obj":"Gene"},{"id":"1014","span":{"begin":36,"end":48},"obj":"Chemical"}],"attributes":[{"id":"A1007","pred":"pubann:denotes","subj":"1007","obj":"Gene:1493"},{"id":"A1014","pred":"pubann:denotes","subj":"1014","obj":"MESH:C520704"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T291","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T654","span":{"begin":60,"end":66},"obj":"Protein"}],"attributes":[{"id":"A654","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q9XSI1"},{"id":"A655","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q9UKN9"},{"id":"A656","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q9TT02"},{"id":"A657","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q9QZZ7"},{"id":"A658","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q9MYX7"},{"id":"A659","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q96P43"},{"id":"A660","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q8WXJ1"},{"id":"A661","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q5S005"},{"id":"A662","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q53TD5"},{"id":"A663","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q52MC1"},{"id":"A664","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/Q0PP65"},{"id":"A665","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/P42072"},{"id":"A666","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/P16410"},{"id":"A667","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/P09793"},{"id":"A668","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/O95653"},{"id":"A669","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/E9PDH0"},{"id":"A670","pred":"uniprot_id","subj":"T654","obj":"https://www.uniprot.org/uniprot/A0N1S0"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T399","span":{"begin":67,"end":75},"obj":"Body_part"},{"id":"T400","span":{"begin":97,"end":105},"obj":"Body_part"},{"id":"T401","span":{"begin":148,"end":153},"obj":"Body_part"}],"attributes":[{"id":"A399","pred":"fma_id","subj":"T399","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A400","pred":"fma_id","subj":"T400","obj":"http://purl.org/sig/ont/fma/fma13478"},{"id":"A401","pred":"fma_id","subj":"T401","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T117","span":{"begin":125,"end":129},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T117","span":{"begin":125,"end":129},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T117","span":{"begin":125,"end":129},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}

{"project":"LitCovid-sentences","denotations":[{"id":"T291","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98"}